두경부암에서의 카테콜아민(에피네프린/노르에피네프린)과 베타차단제의 역할
The Role of Catecholamines (Epinephrine/Norepinephrine) and Beta Blocker in Head and Neck Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Beta blockers are used for various indications, particularly cardiac arrhythmias, cardioprotec-tion after myocardial infarction, hypertension, migraine, tremor, and anxiety disorders, by in-hibiting the sympathetic actions of catecholamine hormones (i.e., epinephrine and norepineph-rine). This sympathetic mechanism occurs via beta-adrenergic receptors. Recently, experimentalevidence showed that malignant cell lines express beta-adrenergic receptors and that sympa-thomimetic neurotransmitters may affect carcinogenesis through these receptors. These neu-rotransmitters are suggested to have a major impact on secondary tumor growth and to con-tribute to metastasis, induction of angiogenesis, and tissue invasion. Given that beta-blockersare considered safe, cheap, and effective, the potential beneficial effects of their use for cancerwould be of interest. However, evidence from epidemiological and clinical studies has beeninconclusive. Especially the effect of beta-blockers on head and neck cancer has rarely been investigated.
Abstract
Beta blockers are used for various indications, particularly cardiac arrhythmias, cardioprotec-tion after myocardial infarction, hypertension, migraine, tremor, and anxiety disorders, by in-hibiting the sympathetic actions of catecholamine hormones (i.e., epinephrine and norepineph-rine). This sympathetic mechanism occurs via beta-adrenergic receptors. Recently, experimentalevidence showed that malignant cell lines express beta-adrenergic receptors and that sympa-thomimetic neurotransmitters may affect carcinogenesis through these receptors. These neu-rotransmitters are suggested to have a major impact on secondary tumor growth and to con-tribute to metastasis, induction of angiogenesis, and tissue invasion. Given that beta-blockersare considered safe, cheap, and effective, the potential beneficial effects of their use for cancerwould be of interest. However, evidence from epidemiological and clinical studies has beeninconclusive. Especially the effect of beta-blockers on head and neck cancer has rarely been investigated.
참고문헌 (25)
- Li P, "Research progress of circRNAs in head and neck cancers", Front Oncol, 11, pp.616202~ (2021)
- Motiejunaite J, "Adrenergic receptors and cardiovascular effects of catecholamines", Ann Endocrinol(Paris), 82(3-4), pp.193~197 (2021)
- Guo K, "Norepinephrineinduced invasion by pancreatic cancer cells is inhibited by propranolol", Oncol Rep, 22(4), pp.825~830 (2009)
- Yang EV, "Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: Implications for stress-related enhancement of tumor progression", Brain Behav Immun, 23(2), pp.267~275 (2009)
- Patel PR, "Norepinephrine reduces reactive oxygen species(ROS)and DNA damage in ovarian surface epithelial cells", J Bioanal Biomed, 7(3), pp.75~80 (2015)
- Silverman DA, "Cancer-associated neurogenesis and nerve-cancer crosstalk", Cancer Res, 81(6), pp.1431~1440 (2021)
- Cole SW, "Molecular pathways : Beta-adrenergic signaling in cancer", Clin Cancer Res, 18(5), pp.1201~1206 (2012)
- Weberpals J, "Beta blockers and cancer prognosis – The role of immortal time bias : A systematic review and meta-analysis", Cancer Treat Rev, 47, pp.1~11 (2016)
- Yap A, "Effect of beta-blockers on cancer recurrence and survival : A meta-analysis of epidemiological and perioperative studies", Br J Anaesth, 121(1), pp.45~57 (2018)
- Haldar R, "Perioperative COX2 and β-adrenergic blockade improves biomarkers of tumor metastasis, immunity, and inflammation in colorectal cancer: A randomized controlled trial", Cancer, 126(17), pp.3991~4001 (2020)
- Kim MS, "Pre-diagnostic beta-blocker use and head- and neck cancer risk: A nationwide population-based casecontrol study", Medicine(Baltimore), 98(24), pp.e16047~ (2019)
- Kwon SY, "β2-adrenergic receptor expression and the effects of norepinephrine and propranolol on various head and neck cancer subtypes", Oncol Lett, 22(5), pp.804~ (2021)
- Shang ZJ, "Expression of beta2-adrenergic receptor in oral squamous cell carcinoma", J Oral Pathol Med, 38(4), pp.371~376 (2009)
- Bernabé DG, "Stress hormones increase cell proliferation and regulates interleukin-6 secretion in human oral squamous cell carcinoma cells", Brain Behav Immun, 25(3), pp.574~583 (2011)
- Bravo-Calderón DM, "Prognostic significance of beta-2 adrenergic receptor in oral squamous cell carcinoma", Cancer Biomark, 10(1), pp.51~59 (2012)
- Vilardi BM, "VEGF-C expression in oral cancer by neurotransmitterinduced activation of beta-adrenergic receptors", Tumour Biol, 34(1), pp.139~143 (2013)
- Xie H, "Chronic stress promotes oral cancer growth and angiogenesis with increased circulating catecholamine and glucocorticoid levels in a mouse model", Oral Oncol, 51(11), pp.991~997 (2015)
- Bravo-Calderón DM, "Beta adrenergic receptor activation inhibits oral cancer migration and invasiveness", Arch Oral Biol, 118, pp.104865~ (2020)
- Zhang B, "The stress hormone norepinephrine promotes tumor progression through β2-adrenoreceptors in oral cancer", Arch Oral Biol, 113, pp.104712~ (2020)
- Zhang C, "Overexpression of β-adrenergic receptors and the suppressive effect of β2-adrenergic receptor blockade in oral squamous cell carcinoma", J Oral Maxillofac Surg, 78(10), pp.1871~ (2020)
- Yang EV, "Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells", Cancer Res, 66(21), pp.10357~10364 (2006)
- Wolter NE, "Propranolol as a novel adjunctive treatment for head and neck squamous cell carcinoma", J Otolaryngol Head Neck Surg, 41(5), pp.334~344 (2012)
- Bastos DB, "Circulating catecholamines are associated with biobehavioral factors and anxiety symptoms in head and neck cancer patients", PLoS One, 13(8), pp.e0202515~ (2018)
- Chang PY, "Propranolol reduces cancer risk: A population-based cohort study", Medicine(Baltimore), 94(27), pp.e1097~ (2015)
- Kim SA, "Postdiagnostic use of β-blockers and other antihypertensive drugs and the risk of recurrence and mortality in head and neck cancer patients: An observational study of 10,414 person-years of followup", Clin Transl Oncol, 19(7), pp.826~833 (2017)